Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

KB001

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Anti‐PcrV antibody in cystic fibrosis: A novel approach targeting Pseudomonas aeruginosa airway infection
Pseudomonas aeruginosa (Pa) airway infection is associated with increased morbidity and mortality in cystic fibrosis (CF). The… Expand
2014
2014
Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa
Pseudomonas aeruginosa is an opportunistic bacterial pathogen that causes fatal acute lung infections in critically ill… Expand
2014
2014
Microbiological Quality of Water Served at Various Pre-School of Delhi
Safety of water is a critical issue in any school food program. Adopting good manufacturing practices in school and day care… Expand
Review
2013
Review
2013
Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis.
BACKGROUND Cystic fibrosis is a multi-system disease characterised by the production of thick secretions causing recurrent… Expand
Highly Cited
2012
Highly Cited
2012
Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: A randomized,double-blind, placebo…
Objective: The type III secretion system is an important Pseudomonas aeruginosa-virulence determinant in animal models of… Expand
2012
2012
Ventilator-associated pneumonia caused by Pseudomonas aeruginosa: cap your needles!
  • A. Hauser
  • Critical care medicine
  • 2012
    • Corpus ID: 28069111
The advent of the recombinant DNA revolution, which made available powerful techniques such as cloning and mutational analyses… Expand
2010
2010
A Pilot Study Of The HumaneeredTM Anti-PcrV Monoclonal Antibody, KB001, In Mechanically-Ventilated (MV) Subjects Colonized With Pseudomonas Aeruginosa (Pa)
 
2010
2010
Modulating Pseudomonas aeruginosa chronic Inflammation With The Anti-PcrV Antibody KB001: Results Of A Pilot Clinical and Pharmacodynamic Study In Subjects With Cystic Fibrosis
 
2009
2009
A Phase I/II Study of the Anti-PcrV Antibody KB001 in Cystic Fibrosis Patients with Pseudomonas aeruginosa.
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE